LEVEMIR FLEXTOUCH (insulin detemir) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2005.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
Levemir FlexTouch is a long-acting basal insulin analog (insulin detemir) administered subcutaneously via a prefilled, disposable pen device. It provides steady, peakless insulin coverage for patients with type 1 and type 2 diabetes who require basal insulin therapy. The drug mimics the body's natural background insulin secretion to maintain glycemic control between meals and overnight.
Product faces imminent loss of exclusivity with moderate Part D spending; team focus shifting toward lifecycle management and generic transition strategy.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Worked on LEVEMIR FLEXTOUCH at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$184M Medicare spend — this is a commercially significant brand
Working on Levemir FlexTouch offers limited growth trajectory due to approaching loss of exclusivity and declining clinical trial activity; career value lies in managing mature product decline, defending market share against generics/biosimilars, and supporting transition to next-generation Novo Nordisk diabetes therapies. This role is best suited for early-career professionals seeking hands-on commercial execution or mid-career professionals transitioning from growth-stage products to lifecycle management.